Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells

J. Vobořilová, V. Němcová-Fürstová, J. Neubauerová, I. Ojima, I. Zanardi, I. Gut, J. Kovář,

. 2011 ; 29 (3) : 411-23.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12028004

Grantová podpora
NR9426 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1997-01-01 do 2017-12-31

The aim of this study is to compare the effects of new fluorinated taxanes SB-T-12851, SB-T-12852, SB-T-12853, and SB-T-12854 with those of the classical taxane paclitaxel and novel non-fluorinated taxane SB-T-1216 on cancer cells. Paclitaxel-sensitive MDA-MB-435 and paclitaxel-resistant NCI/ADR-RES human cancer cell lines were used. Cell growth and survival evaluation, colorimetric assessment of caspases activities, flow cytometric analyses of the cell cycle and the assessment of mitochondrial membrane potential, reactive oxygen species (ROS) and the release of cytochrome c from mitochondria were employed. Fluorinated taxanes have similar effects on cell growth and survival. For MDA-MB-435 cells, the C(50) of SB-T-12851, SB-T-12852, SB-T-12853 and SB-T-12854 was 3 nM, 4 nM, 3 nM and 5 nM, respectively. For NCI/ADR-RES cells, the C(50) of SB-T-12851, SB-T-12852, SB-T-12853, and SB-T-12854 was 20 nM, 20 nM, 10 nM and 10 nM, respectively. Selected fluorinated taxanes, SB-T-12853 and SB-T-12854, at the death-inducing concentrations (30 nM for MDA-MB-435 and 300 nM for NCI/ADR-RES) were shown to activate significantly caspase-3, caspase-9, caspase-2 and also slightly caspase-8. Cell death was associated with significant accumulation of cells in the G(2)/M phase. Cytochrome c was not released from mitochondria and other mitochondrial functions were not significantly impaired. The new fluorinated taxanes appear to use the same or similar mechanisms of cell death induction as compared with SB-T-1216 and paclitaxel. New fluorinated and non-fluorinated taxanes are more effective against drug-resistant cancer cells than paclitaxel. Therefore, new generation of taxanes, either non-fluorinated or fluorinated, are excellent candidates for further and detailed studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12028004
003      
CZ-PrNML
005      
20140326134028.0
007      
ta
008      
120817s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1007/s10637-009-9368-8 $2 doi
035    __
$a (PubMed)20013348
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vobořilová, Jana $u Department of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Ruská 87, 10000, Prague 10, Czech Republic.
245    10
$a Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells / $c J. Vobořilová, V. Němcová-Fürstová, J. Neubauerová, I. Ojima, I. Zanardi, I. Gut, J. Kovář,
520    9_
$a The aim of this study is to compare the effects of new fluorinated taxanes SB-T-12851, SB-T-12852, SB-T-12853, and SB-T-12854 with those of the classical taxane paclitaxel and novel non-fluorinated taxane SB-T-1216 on cancer cells. Paclitaxel-sensitive MDA-MB-435 and paclitaxel-resistant NCI/ADR-RES human cancer cell lines were used. Cell growth and survival evaluation, colorimetric assessment of caspases activities, flow cytometric analyses of the cell cycle and the assessment of mitochondrial membrane potential, reactive oxygen species (ROS) and the release of cytochrome c from mitochondria were employed. Fluorinated taxanes have similar effects on cell growth and survival. For MDA-MB-435 cells, the C(50) of SB-T-12851, SB-T-12852, SB-T-12853 and SB-T-12854 was 3 nM, 4 nM, 3 nM and 5 nM, respectively. For NCI/ADR-RES cells, the C(50) of SB-T-12851, SB-T-12852, SB-T-12853, and SB-T-12854 was 20 nM, 20 nM, 10 nM and 10 nM, respectively. Selected fluorinated taxanes, SB-T-12853 and SB-T-12854, at the death-inducing concentrations (30 nM for MDA-MB-435 and 300 nM for NCI/ADR-RES) were shown to activate significantly caspase-3, caspase-9, caspase-2 and also slightly caspase-8. Cell death was associated with significant accumulation of cells in the G(2)/M phase. Cytochrome c was not released from mitochondria and other mitochondrial functions were not significantly impaired. The new fluorinated taxanes appear to use the same or similar mechanisms of cell death induction as compared with SB-T-1216 and paclitaxel. New fluorinated and non-fluorinated taxanes are more effective against drug-resistant cancer cells than paclitaxel. Therefore, new generation of taxanes, either non-fluorinated or fluorinated, are excellent candidates for further and detailed studies.
650    _2
$a kaspasy $x metabolismus $7 D020169
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a buněčná smrt $x účinky léků $7 D016923
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cytochromy c $x sekrece $7 D045304
650    _2
$a DNA nádorová $x metabolismus $7 D004273
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a sloučeniny fluoru $x chemie $x farmakologie $7 D017611
650    _2
$a lidé $7 D006801
650    _2
$a mitochondrie $x účinky léků $x metabolismus $7 D008928
650    _2
$a paclitaxel $x chemie $x farmakologie $7 D017239
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a taxoidy $x chemie $x farmakologie $7 D043823
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Němcová-Fürstová, Vlasta
700    1_
$a Neubauerová, Jitka
700    1_
$a Ojima, Iwao
700    1_
$a Zanardi, Ilaria
700    1_
$a Gut, Ivan
700    1_
$a Kovář, Jan
773    0_
$w MED00008129 $t Investigational new drugs $x 1573-0646 $g Roč. 29, č. 3 (2011), s. 411-23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20013348 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20140326134102 $b ABA008
999    __
$a ok $b bmc $g 950046 $s 785350
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 29 $c 3 $d 411-23 $i 1573-0646 $m Investigational new drugs $n Invest New Drugs $x MED00008129
GRA    __
$a NR9426 $p MZ0
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...